基础疾病儿童接种13价肺炎球菌结合疫苗的免疫原性
研究纳入12–71月龄HIV感染、肾脏疾病和肺部疾病儿童(高危组)及健康对照,高危组接种两剂PCV13、对照组接种一剂。所有组均产生免疫应答,高危组应答大多与对照相似;HIV感染儿童三个血清型GMC较低,肾脏病儿童6B型较高,肺病儿童6B和14型较高;所有组对3型和19A型应答减弱。
要点
- 高危组与对照组首剂后抗体≥4倍增长比例相似。
- HIV感染儿童三个血清型GMC低于对照。
- 所有组对3型和19A型应答减弱,高危组更明显。
核心结论
- 所有研究组均对PCV13产生免疫应答,高危组应答大多与健康对照儿童相似。
研究设计与样本
- 研究纳入12–71月龄HIV感染、肾脏疾病和肺部疾病儿童(高危组)及健康对照儿童,高危组接种两剂PCV13,对照组接种一剂。
- 采用基于Luminex的酶免疫测定法检测基线和接种后全部PCV13血清型特异性抗体。
主要发现
- 首剂PCV13后,对照组与高危组血清型特异性抗体几何平均浓度(GMC)较基线的倍数增长及抗体浓度≥4倍增长参与者百分比相似。
- HIV感染儿童13个血清型中3个血清型GMC较低;肾脏疾病儿童6B型GMC较高;肺部疾病儿童6B和14型GMC较高。
- HIV感染儿童第二剂后9个血清型GMC较首剂后升高,但除6A和19F型外,第二剂后较基线≥4倍增长参与者百分比与首剂后相似。
- 肾脏或肺部疾病儿童第二剂后免疫应答与首剂后相似。
- 所有研究组对3型和19A型应答减弱,高危组尤为明显。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Streptococcus pneumoniae is a leading cause of vaccine-preventable disease in children under 5years. Immunocompromised children and those with underlying diseases are at increased risk of severe complications from vaccine-preventable infections. We studied the humoral immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in children with HIV-infection, kidney or lung disease and compared this to the response in healthy control children. METHODS: Children aged 12-71months with underlying conditions including HIV-infection and those with kidney and lung diseases (at-risk children), and a healthy control group were vaccinated with PCV13. The at-risk children received two doses of PCV13 and the controls received one dose. Serotype-specific antibodies for all PCV13 serotypes were measured by a luminex-based enzyme immunoassay at baseline and post-vaccination. RESULTS: After the first PCV13 dose, the fold-increase in serotype-specific antibody geometric mean concentrations (GMCs) from baseline and the percentage of participants with ≥4-fold-increase in antibody concentrations was similar between the control and at-risk children. GMCs were, however, lower for three of the 13 serotypes in HIV-infected children, higher for serotype 6B in children with kidney disease and higher for serotypes 6B and 14 in children with lung disease. After second vaccine dose HIV-infected children had an increase in GMCs from post-first dose for nine serotypes but the percentage of participants with ≥4-fold-increase from baseline was similar post-second dose compared to post-first dose except for serotypes 6A and 19F. In children with kidney or lung diseases the immune responses after second vaccine dose were similar to post-first dose. Attenuated responses were observed for serotypes 3 and 19A in all study-groups, which was especially pronounced in the at-risk groups. CONCLUSION: All study-groups mounted an immune response to PCV13, with the at-risk groups having responses that were mostly similar to the control children.
引用
- Jallow S, Madhi SA, Madimabe R, et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017. PMID: 28688781. doi:10.1016/j.vaccine.2017.06.081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。